A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX43.

Phase 1

Shanghai Henlius Biotech